<DOC>
	<DOCNO>NCT01170923</DOCNO>
	<brief_summary>The usual response chemotherapy decide image change compute tomography ( CT ) , take least 6-9 week . In order predict response chemotherapy earlier , patient receive FDG-PET scan first cycle chemotherapy . Chemotherapy guide metabolic response FDG-PET scan .</brief_summary>
	<brief_title>FDG-PET Scan Response Guided Chemotherapy Strategy Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Prospective , Open-label , Randomized phase II , single institution trial compare chemotherapy guide traditional evaluation base RECIST versus chemotherapy guide FDG-PET ( metabolic ) response .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Histologically confirm nonsmall cell carcinoma . 2 . Stage IIIB ( wet ) IV advance NSCLC . 3 . No evidence prior malignancies 3 year except treat basal cell squamous cell carcinoma skin carcinoma situ uterine cervix . 4 . Measurable disease RECIST criterion . 5 . Adequate organ function follow . Seum AST/ALT &lt; 2.5 x Upper normal limit ( UNL ) ( hepatic metastasis &lt; 5 x UNL ) Total bilirubin &lt; 1.5 x UNL Serum creatinine &lt; 1.5 mg/dL Absolute neutrophil count &gt; 1500/uL Platelet &gt; 100,000/uL Hemoglobin &gt; 9.0 g/dL 6 . ECOG Performance status 01 7 Age &gt; 18 8 . If previously treat major surgery , least 4 week . And previously treat radiotherapy , least 2 week . 9 . Written consent 1 . Previous chemotherapy . 2 . Symptomatic brain metastasis . 3 . Concurrent severe medical illness . 4 . Pregnancy lactation . 5 . If finding may increase risk chemotherapy inhibit analyze result clinical trial . Uncontrolled diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>FDG PET</keyword>
</DOC>